Form D · Biotechnology
Sapience Therapeutics, Inc.
Harrison, NY · CIK 0001661731
Offering snapshot reported Jul 13, 2020 · SEC filing
- Reported sold
- $8.01M Offering amount: $30M
- Investors reported
- 83 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jun 29, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 13, 2020 | Initial | $8,010,876 | No comparison | 83 | SEC filing |
| Apr 5, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 11, 2016 | Initial | $300,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $701K
- Finders' fees
- $0
- Form D file number
- 021-370845
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 12078 |
Source: Form D, filed Jul 13, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Isaac Blech | Director |
| Barry Kappel | Director, Executive |
| Barry Kappel, Ph.D. | Director, Executive |
| Howard Pien | Director |
| Robert Ruffolo | Director |
| Robert Ruffolo, Ph.D. | Director |
| Christian Schade | Director |
| David Scheinberg | Director |
| David Scheinberg, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
500 Mamaroneck Avenue Suite 320
Harrison, NY, 10528
Harrison, NY, 10528